Smith & Nephew plc (SNN) Stock
SNN Key Statistics
About Smith & Nephew plc
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
CEO: Deepak S. Nath. Company website
SNN — Frequently Asked Questions
What is the SNN stock price today?
Smith & Nephew plc (SNN) trades at $27.56, down 0.79% on the day, as of Sep 20, 2026 15:01 UTC.
What is Smith & Nephew plc's market cap?
Smith & Nephew plc has a market capitalisation of $11.57B, calculated from the live SNN share price and shares outstanding.
What is the P/E ratio of SNN?
SNN trades at a trailing P/E of 18.88, from earnings per share of $1.46 over the last twelve months.
How much revenue does Smith & Nephew plc make?
Smith & Nephew plc generated revenue of $6.30B over the trailing twelve months, which puts the stock at 1.84 times sales.
Does SNN pay a dividend?
Yes. Smith & Nephew plc pays a dividend yielding 2.30% on the current share price.
What is the 52-week range for SNN?
SNN has traded between $27.23 and $37.78 over the past 52 weeks, and the last price is 27.1% below that high.
Is Smith & Nephew plc profitable?
Yes. Smith & Nephew plc keeps 10.08% of revenue as net income over the trailing twelve months.
What is the analyst price target for SNN?
Wall Street analysts rate SNN Hold, with an average price target of $31.91, 15.8% above the current price.
What sector is Smith & Nephew plc in?
Smith & Nephew plc is classified under the Healthcare sector and the Medical - Devices industry, and is domiciled in GB.
Who is the CEO of Smith & Nephew plc?
Deepak S. Nath is the chief executive of Smith & Nephew plc, which employs 18,362 people.
Where can I track SNN in real time?
QFI Terminal shows SNN with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See SNN live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open SNN in Terminal See plans